Gastrointestinal Cancer

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses survival data with TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric cancer at the 2018 ESMO Congress.

Diana L. Hanna, MD, discusses the past, present, and future of treatment for patients with metastatic pancreatic cancer.

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential for precision medicine in hepatocellular carcinoma.

Anthony B. El-Khoueiry, MD, discusses the promising hepatocellular carcinoma treatment paradigm.

Afsaneh Barzi, MD, discusses updates in the treatment of patients with pancreatic cancer, as well as the importance of genetic testing.